BiotechTube

bexmarilimab

Phase 1/2Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 14/100
14
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoma, Renal Cell

Conditions

Carcinoma, Renal Cell, Carcinoma Colon

Trial Timeline

Oct 7, 2021 → Jan 28, 2022

NCT ID
NCT05104905

About bexmarilimab

bexmarilimab is a phase 1/2 stage product being developed by Faron Pharmaceuticals for Carcinoma, Renal Cell. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05104905. Target conditions include Carcinoma, Renal Cell, Carcinoma Colon.

What happened to similar drugs?

20 of 20 similar drugs in Carcinoma, Renal Cell were approved

Approved (20) Terminated (1) Active (0)
✅Enfortumab VedotinAstellas PharmaApproved
✅Sonidegib Phosphate CapsulesSun PharmaceuticalApproved
✅LenvatinibEisaiApproved
✅Epirubicin + lipiodolJohnson & JohnsonApproved
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅Olaparib + BevacizumabAstraZenecaApproved

Hype Score Breakdown

Clinical
9
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05104905Phase 1/2Withdrawn

Competing Products

20 competing products in Carcinoma, Renal Cell

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
AFM24 + SNK01AffimedPhase 1/2
14
NRC-2694-A + PaclitaxelNatco PharmaPhase 2
42
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
27
Cemiplimab + CetuximabEli LillyPhase 2
42
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
35
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
26
BB-401Benitec BiopharmaPhase 2
25
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
AzenosertibZentalis PharmaceuticalsPhase 2
25
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
26
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
Ramucirumab + PaclitaxelEli LillyPhase 2
35